Simon Quick Advisors LLC Sells 21,237 Shares of Pfizer Inc. $PFE

Simon Quick Advisors LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 64.7% during the third quarter, Holdings Channel.com reports. The institutional investor owned 11,569 shares of the biopharmaceutical company’s stock after selling 21,237 shares during the quarter. Simon Quick Advisors LLC’s holdings in Pfizer were worth $295,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its stake in Pfizer by 6.2% in the third quarter. Signaturefd LLC now owns 105,160 shares of the biopharmaceutical company’s stock valued at $2,679,000 after acquiring an additional 6,171 shares in the last quarter. Brave Asset Management Inc. increased its position in shares of Pfizer by 8.9% during the third quarter. Brave Asset Management Inc. now owns 14,691 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 1,203 shares in the last quarter. Bell Bank lifted its holdings in shares of Pfizer by 5.3% during the 3rd quarter. Bell Bank now owns 457,094 shares of the biopharmaceutical company’s stock valued at $11,647,000 after purchasing an additional 23,111 shares during the last quarter. GAM Holding AG acquired a new stake in shares of Pfizer in the 3rd quarter worth $249,000. Finally, Quattro Financial Advisors LLC boosted its position in shares of Pfizer by 1.6% in the 3rd quarter. Quattro Financial Advisors LLC now owns 50,800 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 800 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Morgan Stanley lowered their target price on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Citigroup assumed coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, Scotiabank initiated coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $28.06.

Pfizer Stock Performance

NYSE PFE opened at $25.17 on Monday. The stock has a market capitalization of $143.13 billion, a price-to-earnings ratio of 14.64 and a beta of 0.47. The stock has a 50-day moving average of $25.18 and a 200 day moving average of $24.92. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: BMO Capital reaffirmed an Outperform rating and a $30 price target, citing Pfizer’s cost controls and a cautious-but-manageable 2026 outlook — a clear vote of confidence for investors focused on valuation and income. BMO reaffirmation
• Positive Sentiment: Multiple bullish analyst/publication pieces argue Pfizer is undervalued and that its pipeline plus deal-making (Seagen, recent obesity-related buys) position it to recover over time — supporting a value-oriented rally. See Fool’s take on medium-term upside. 2 Predictions for Pfizer in 2026
• Positive Sentiment: Analysts at Zacks raised certain near-term quarterly EPS estimates (Q2 2026/Q2 2027), which can help sentiment around upcoming reports and show some upside to consensus in select periods.
• Neutral Sentiment: In-depth pieces (Seeking Alpha, Yahoo Finance) frame 2026 as a “reset” year: higher R&D and acquisition-driven repositioning (notably the Metsera deal) should strengthen Pfizer’s obesity and oncology lineup, but benefits may take time to show. Pfizer 2026: The Reset Year Why Wall Street Gave Up on Pfizer
• Neutral Sentiment: Market commentary reiterates Pfizer’s cheap forward valuation versus peers and highlights that recent M&A (Seagen, Metsera) is beginning to add revenue and late‑stage assets — a longer‑term positive but not immediate earnings relief.
• Negative Sentiment: Pfizer disclosed a death in a long‑term Hympavzi study after a thrombotic stroke — a safety event that could weigh on that program’s outlook and near‑term sentiment. Hympavzi study death
• Negative Sentiment: Analyst estimate trims and management comments point to earnings pressure from the post‑COVID revenue decline and dilution from acquisitions; Zacks trimmed a Q4 EPS estimate — reinforcing near‑term earnings uncertainty.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.